|
MED21 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.85991238971428E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.16240367226328E-11 |
| Normal-vs-Stage2 |
7.2068999656949E-09 |
| Normal-vs-Stage3 |
1.31006316905768E-14 |
| Normal-vs-Stage4 |
1.74438241629105E-12 |
| Stage1-vs-Stage2 |
7.650600E-01 |
| Stage1-vs-Stage3 |
1.640360E-01 |
| Stage1-vs-Stage4 |
2.168500E-02 |
| Stage2-vs-Stage3 |
5.243600E-01 |
| Stage2-vs-Stage4 |
1.270020E-01 |
| Stage3-vs-Stage4 |
2.647600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.18680000271709E-08 |
| Normal-vs-Asian |
9.34360366855458E-11 |
| Caucasian-vs-AfricanAmerican |
7.965200E-01 |
| Caucasian-vs-Asian |
6.381600E-01 |
| AfricanAmerican-vs-Asian |
9.274000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
2.05000461050986E-11 |
| Male-vs-Female |
3.262100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.68964842117703E-12 |
| Normal-vs-Age(41-60Yrs) |
3.5527136788005E-15 |
| Normal-vs-Age(61-80Yrs) |
6.3726801613484E-14 |
| Normal-vs-Age(81-100Yrs) |
7.824900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.835400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.410030E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.333600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.720400E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.740000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.202400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.921400E-01 |
| Classical-VS-Follicular |
2.553800E-01 |
| Classical-VS-Other |
9.701000E-01 |
| Classical-VS-Normal |
1.61660018704879E-10 |
| Tall-VS-Follicular |
8.921400E-01 |
| Tall-VS-Other |
7.652600E-01 |
| Tall-VS-Normal |
5.93480042887506E-10 |
| Follicular-VS-Other |
7.622800E-01 |
| Follicular-VS-Normal |
2.35189645536593E-11 |
| Other-VS-Normal |
6.884500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.33066907387547E-16 |
| Normal-vs-N1 |
2.31326069410898E-12 |
| N0-vs-N1 |
1.199010E-01 |
|
|
